Journal
KIDNEY INTERNATIONAL
Volume 86, Issue 4, Pages 676-678Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2014.179
Keywords
-
Categories
Ask authors/readers for more resources
Optimal treatment algorithms for erythropoiesis-stimulating agent (ESA) and iron therapy in anemic CKD patients are lacking. Kuragano et al. evaluated hemodialysis patients over two years and report increased mortality risk and/or adverse events in those with high serum ferritin levels and high ferritin fluctuations, and an increase in adverse events in iron users. Clinical practice should avoid disproportionately high ESA or iron doses to achieve hemoglobin targets, particularly in those with significant comorbidity or ESA resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available